BCM
ICPT

Bluefin Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Bluefin Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-61,800
Closed -$12K – 709
2019
Q4 		$12K Sell
61,800
-26,800
-30% -$2.4M ﹤0.01% 529
2019
Q3 		$936K Buy
+88,600
New +$5.95M 0.14% 118

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Bluefin Capital Management's ICPT Position: Q3 2015 in Review

Bluefin Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2015, closing a stake of 1,700 shares — an estimated $410K sold.

Bluefin Capital Management first reported a position in ICPT in Q2 2015 and held it in 1 quarter. The position peaked at $410K in Q2 2015. 173 funds tracked by Wall St. Rank hold ICPT as of Q3 2015.

  • Bluefin Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Bluefin Capital Management sold 1,700 Intercept Pharmaceuticals, Inc. shares in Q3 2015, an estimated $410K.
  • Bluefin Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2015 and held it in 1 quarter.
  • Bluefin Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $410K in Q2 2015.
  • 173 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2015.

Based on Bluefin Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.